View Clinical Trial (Medical Research Study)

Efficacy and Safety of Zoledronic Acid in Acute Spinal Cord Injury: Prevention of Bone Loss - NCT00844480-60611(Clinical Trial 272134)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Chicago
State:  
IL
Zip Code: 60611
Conditions: Bone Loss
Purpose: This is a double-blind, randomized, placebo-controlled trial of zoledronic acid, 5mg, to be administered intravenously to people who have suffered an acute spinal cord fracture. The goal is to evaluate if zoledronic acid can prevent the acute bone loss seen in this population. Outcome measures will include bone density determinations over a one year period.
Study summary:
Criteria: Inclusion Criteria: 1. In-patient at RIC 2. Men and women 3. Age 18 years and older 4. Spinal cord injury within 8 weeks of study entry 5. ASIA A or B 6. Medically stable in the opinion of their physiatrist 7. Able to have dexa performed 8. Able to return for follow-up at 6 and 12 months Exclusion Criteria: 1. Vitamin D deficiency 2. Hypocalcemia 3. Renal insufficiency (estimated creatinine clearance <30ml/min) 4. Abnormal thyroid hormone status 5. Abnormal mental status 6. Osteoporosis at the hip or spine by dexa
Study is available at: Rehabilitation Institute of Chicago
Chicago, IL 60611
United States

Primary Contact:
Lisa Streff
Email: lstreff@ric.org
Phone: 312-238-2816
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 23, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.